Clinical Value of Prenatal Screening Markers in Early Pregnancy Combined with Perinatal Characteristics to Predict Fetal Growth Restriction

Overview

Journal Transl Pediatr

Publisher AME Publishing Company

Specialty Pediatrics

Date 2024 Aug 15

PMID 39144423

Authors

Yiming Chen

Xiaoqing Dai

Tingting Hu

Chen Jiang

Yongmiao Pan

Affiliations

Soon will be listed here.

Abstract

Background: Due to the incomplete standardization of the etiology and diagnostic criteria for fetal growth restriction (FGR), there has been uncertainty in the early prediction of FGR. The comprehensive estimation of FGR was mainly based on various factors, such as maternal characteristics and medical history, nuchal translucency (NT), and serum biochemical markers [pregnancy-associated plasma protein-A (PAPP-A) and free beta human chorionic gonadotropin (free β-hCG)]. Herein, we performed a retrospective cohort study to investigate the correlation and diagnostic value of maternal markers such as PAPP-A, free β-hCG, and NT in the first trimester with maternal characteristics, so as to provide theoretical basis for perinatal care and the application of low-dose aspirin.

Methods: A retrospective cohort study was conducted to analyze the data of an FGR group and a non-FGR group. Chi-square test and Mann-Whitney test were used for univariate analysis of qualitative or quantitative data, respectively. Modified Poisson regression calculated the relative risk (RR) and 95% confidence interval (CI) of perinatal variables; P<0.05 was considered statistically significant.

Results: The multiple of median (MoM) of PAPP-A level and NT in the FGR group were lower than those of the non-FGR group [0.63 (0.12-2.08) 1.01 (0.28-2.41) MoM, 1.30 (0.80-2.07) 1.40 (0.80-2.20) cm, P<0.05]. The weight, score, and length of newborns in the FGR group were lower than those in the non-FGR group (all P<0.001). Modified Poisson regression analysis showed that gestational hypertension (GH) [RR =1.836 (95% CI: 1.188-2.836)], oligohydramnios [1.420 (95% CI: 1.022-1.973)], premature rupture of membranes (PROM) [0.641 (95% CI: 0.425-0.969)], female infant [1.539 (95% CI: 1.098-2.157)], low infant length [5.700 (95% CI: 3.416-9.509)], low birth weight [1.609 (95% CI: 1.012-2.559), and increased PAPP-A MoM [0.533 (95% CI: 0.369-0.769)] were associated with FGR. The cut-off value of PAPP-A + free β-hCG + NT for predicting FGR was 0.190, with a sensitivity of 0.547 and a specificity of 0.778.

Conclusions: Early screening markers combined with perinatal characteristics have better diagnostic value in predicting FGR and provide a scientific basis for the clinical use of low-dose aspirin to prevent FGR.

References

Berezowsky A, Pardo J, Ben-Zion M, Wiznitzer A, Aviram A . Second Trimester Biochemical Markers as Possible Predictors of Pathological Placentation: A Retrospective Case-Control Study. Fetal Diagn Ther. 2019; 46(3):187-192. DOI: 10.1159/000492829. View

Whelan A, Has P, Savitz D, Danilack V, Lewkowitz A . Neonatal Outcomes Are Similar between Patients with Resolved and Those with Persistent Oligohydramnios. Am J Perinatol. 2024; 41(10):1285-1289. PMC: 11223946. DOI: 10.1055/a-2278-8948. View

Darendeliler F . IUGR: Genetic influences, metabolic problems, environmental associations/triggers, current and future management. Best Pract Res Clin Endocrinol Metab. 2019; 33(3):101260. DOI: 10.1016/j.beem.2019.01.001. View

Jiang M, Mishu M, Lu D, Yin X . A case control study of risk factors and neonatal outcomes of preterm birth. Taiwan J Obstet Gynecol. 2018; 57(6):814-818. DOI: 10.1016/j.tjog.2018.10.008. View

Farzad Mohajeri Z, Aalipour S, Sheikh M, Shafaat M, Hantoushzadeh S, Borna S . Ultrasound measurement of fetal adrenal gland in fetuses with intrauterine growth restriction, an early predictive method for adverse outcomes. J Matern Fetal Neonatal Med. 2017; 32(9):1485-1491. DOI: 10.1080/14767058.2017.1410125. View

Dinglas C, Afsar N, Cochrane E, Davis J, Kim S, Akerman M . First-trimester maternal serum alpha fetoprotein is associated with ischemic placental disease. Am J Obstet Gynecol. 2019; 222(5):499.e1-499.e6. DOI: 10.1016/j.ajog.2019.11.1264. View

Loussert L, Vidal F, Parant O, Hamdi S, Vayssiere C, Guerby P . Aspirin for prevention of preeclampsia and fetal growth restriction. Prenat Diagn. 2020; 40(5):519-527. DOI: 10.1002/pd.5645. View

Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E . The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol. 2016; 216(2):110-120.e6. DOI: 10.1016/j.ajog.2016.09.076. View

Chatmethakul T, Roghair R . Risk of hypertension following perinatal adversity: IUGR and prematurity. J Endocrinol. 2019; 242(1):T21-T32. PMC: 6594910. DOI: 10.1530/JOE-18-0687. View

10.

Jain V . Letter to the Editor: Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy: Executive Summary. J Obstet Gynaecol Can. 2015; 37(9):774-775. DOI: 10.1016/S1701-2163(15)30145-6. View

11.

Goetzinger K, Singla A, Gerkowicz S, Dicke J, Gray D, Odibo A . The efficiency of first-trimester serum analytes and maternal characteristics in predicting fetal growth disorders. Am J Obstet Gynecol. 2009; 201(4):412.e1-6. DOI: 10.1016/j.ajog.2009.07.016. View

12.

Ormesher L, Warrander L, Liu Y, Thomas S, Simcox L, Smith G . Risk stratification for early-onset fetal growth restriction in women with abnormal serum biomarkers: a retrospective cohort study. Sci Rep. 2020; 10(1):22259. PMC: 7746767. DOI: 10.1038/s41598-020-78631-5. View

13.

Mohamad Jafari R, Masihi S, Barati M, Maraghi E, Sheibani S, Sheikhvatan M . Value of Pregnancy-Associated Plasma Protein-A for Predicting Adverse Pregnancy Outcome. Arch Iran Med. 2019; 22(10):584-587. View

14.

Audette M, Kingdom J . Screening for fetal growth restriction and placental insufficiency. Semin Fetal Neonatal Med. 2017; 23(2):119-125. DOI: 10.1016/j.siny.2017.11.004. View

15.

Lewandowska M, Wieckowska B, Sztorc L, Sajdak S . Smoking and Smoking Cessation in the Risk for Fetal Growth Restriction and Low Birth Weight and Additive Effect of Maternal Obesity. J Clin Med. 2020; 9(11). PMC: 7692695. DOI: 10.3390/jcm9113504. View

16.

. ACOG Practice bulletin no. 134: fetal growth restriction. Obstet Gynecol. 2013; 121(5):1122-1133. DOI: 10.1097/01.AOG.0000429658.85846.f9. View

17.

Honarjoo M, Zarean E, Tarrahi M, Kohan S . Role of pregnancy-associated plasma protein A (PAPP-A) and human-derived chorionic gonadotrophic hormone (free β-hCG) serum levels as a marker in predicting of Small for gestational age (SGA): A cohort study. J Res Med Sci. 2022; 26:104. PMC: 8765518. DOI: 10.4103/jrms.JRMS_560_20. View

18.

. [Guidelines for diagnosis and treatment of intrahepatic cholestasis of pregnancy (2015)]. Zhonghua Fu Chan Ke Za Zhi. 2015; 50(7):481-5. View

19.

Antsaklis P, Fasoulakis Z, Theodora M, Diakosavvas M, Kontomanolis E . Association of Low Maternal Pregnancy-associated Plasma Protein A with Adverse Perinatal Outcome. Cureus. 2019; 11(6):e4912. PMC: 6692091. DOI: 10.7759/cureus.4912. View

20.

. Fetal Growth Restriction: ACOG Practice Bulletin, Number 227. Obstet Gynecol. 2021; 137(2):e16-e28. DOI: 10.1097/AOG.0000000000004251. View